On Monday, Sorrento Therapeutics received clearance from the FDA to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms. That trial could begin as soon as August. Sorrento's stock spiked at the start of this week as a result of the encouraging news. Abivertinib has already completed a registration trial for lung cancer and been administered to over 600 patients worldwide. Dr. Henry Ji, Chairman, President and CEO of Sorrento Therapeutics and Mark Brunswick, SVP of Regulatory Affairs at Sorrento Therapeutics, discuseed what the next phase of testing will involve.